GPC3 and hepatocellular carcinoma: GPC3 was found to suppress the expression and signaling of TGF-β2, which led to activation of cell growth and cell cycle progression [150]; strategies aimed to suppress GPC3 expression were thus proposed as valuable options for the clinical management of GPC3-positive HCC patients.